Rage Biotech
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
655 Elizabeth St Ste 11.107, Melbourne, ...Phone Number
+33 640194770Website
www.ragebiotech.comRevenue
<$5 MillionIndustry
About Rage Biotech
RAGE Biotech is focused on developing innovative therapeutics that target the Receptor for Advanced Glycation End-products (RAGE) to address chronic inflammatory diseases. The company utilizes advanced RNA-targeting and therapeutic peptide technologies to create effective RAGE inhibitors for patients with difficult-to-treat conditions. Their primary aim is to enhance the quality of life for individuals suffering from chronic inflammatory diseases globally. RAGE Biotech's products are particularly relevant for patients with chronic lung diseases such as COPD, severe asthma, and cystic fibrosis.Explore more
Rage Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Rage Biotech
Compare insights from companies similar to Rage Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rage Biotech Tech Stack
A closer look at the technologies used by Rage Biotech
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Rage Biotech
Sign Up For FreeTo access detailed company insights
RAGE Biotech is focused on developing innovative therapeutics that target the Receptor for Advanced Glycation End-products (RAGE) to address chronic inflammatory diseases. The company utilizes advanced RNA-targeting and therapeutic peptide technologies to create effective RAGE inhibitors for patients with difficult-to-treat conditions. Their primar... Read More
